The Epidermal Growth Factor Receptor and Its Ligands in Cardiovascular Disease
AbstractThe epidermal growth factor receptor (EGFR) family and its ligands serve as a switchboard for the regulation of multiple cellular processes. While it is clear that EGFR activity is essential for normal cardiac development, its function in the vasculature and its role in cardiovascular disease are only beginning to be elucidated. In the blood vessel, endothelial cells and smooth muscle cells are both a source and a target of EGF-like ligands. Activation of EGFR has been implicated in blood pressure regulation, endothelial dysfunction, neointimal hyperplasia, atherogenesis, and cardiac remodeling. Furthermore, increased circulating EGF-like ligands may mediate accelerated vascular disease associated with chronic inflammation. Although EGFR inhibitors are currently being used clinically for the treatment of cancer, additional studies are necessary to determine whether abrogation of EGFR signaling is a potential strategy for the treatment of cardiovascular disease. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Makki, N.; Thiel, K.W.; Miller, F.J., Jr. The Epidermal Growth Factor Receptor and Its Ligands in Cardiovascular Disease. Int. J. Mol. Sci. 2013, 14, 20597-20613.
Makki N, Thiel KW, Miller FJ, Jr. The Epidermal Growth Factor Receptor and Its Ligands in Cardiovascular Disease. International Journal of Molecular Sciences. 2013; 14(10):20597-20613.Chicago/Turabian Style
Makki, Nader; Thiel, Kristina W.; Miller, Francis J., Jr. 2013. "The Epidermal Growth Factor Receptor and Its Ligands in Cardiovascular Disease." Int. J. Mol. Sci. 14, no. 10: 20597-20613.